If you have a drug that is $100 for one course of therapy, and you know that you can charge $100,000, what should shareholders think when you say, 'I'd rather not take the heat'?
If you have a drug that is $100 for one course of therapy, and you know that you can charge $100,000, what should shareholders think when you say, 'I'd rather not take the heat'?